Based on our modeled structure, we performed molecular docking to predict putative binding sites of genistein on the dimer. Our prediction of multiple binding sites for gensitein corroborates the measured bell-shaped dose–response relationship of genistein that at low concentrations, genistein enhances the CFTR current [20,21,13](presumably due to genistein’s binding to sites 2 and/or 3) whereas at high concentrations, CFTR current decreases [20,21](presumably due to genistein’s competition with ATP at site 1). The modeling results suggest that an efficient, ideal potentiator should bind to site 3 at the NBD interface but not to site 1 at ATP binding sites, a theory that may be used in the practice of drug design targeting at CFTR.